|Day Low/High||44.12 / 44.67|
|52 Wk Low/High||37.43 / 45.62|
Stocks fall on Thursday afternoon after House leaders delay a highly anticipated vote on the Republicans' repeal-and-replace health care bill.
Why the name is sagging, and what it will take to spur the sector higher.
This biotech name shows no sign of slowing down.
Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.
Absent specific policy details, Trump's speech leaves investors guessing about his real plans for the FDA and the drug approval process. He has not yet named an FDA commissioner.
Hollywood's lack of originality shines through with 15 remakes and sequels this year.
SNY has become much stronger since late October; buy here and above $44.
AstraZeneca shares, meanwhile, were less-than-moved by the news.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
The continuous glucose monitor maker is an excellent growth opportunity.
The Auvi-Q was released Feb. 14, but it's unclear whether patients will break up with their current option, EpiPen, for something new.
The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.
Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.
People living with diabetes have filed a groundbreaking class-action lawsuit against the three makers of analog insulin drug products - Sanofi, Novo Nordisk and Eli Lilly - for exponentially raising consumer insulin prices...
It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.
Other movers included Mannkind, Perrigo and Bristol-Myers Squibb.
Regeneron has faced a lower stock price and patent wrangling. But the stock could be ready to rise again.
Animal health and oncology deal activity is heating up in 2017.
These stocks are showing short-term gain catalysts and longer-term growth potential. Here's how to trade them.
Shares fall on worse-than-expected guidance. It was not a good day for Teva Pharmaceuticals.
After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.
The Medicines Company, Alder also see share boosts on favorable implications. Jim Cramer weighs in on the implications for Amgen investors.
A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.
U.S. stock futures trade slightly lower Friday ahead of the U.S. jobs report for December, the last under the Obama presidency.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.